RSV and the Challenge of Reinfection: Long-Term Prevention Perspectives

This episode tackles an important conceptual challenge: if RSV is a lifelong recurrent infection, what exactly are current preventive strategies protecting against? Dr. Creech explains that the goal is not — and cannot be — the elimination of RSV exposure. Rather, the strategy is to delay the first serious encounter to an age when the infant's immune system is better equipped to manage it. By providing passive antibody protection during the most vulnerable first months of life, clinicians allow infants to encounter RSV — when it inevitably happens — with some residual immune support rather than none.

This framing has an additional benefit: infants protected during initial RSV exposure will still mount immune responses, building natural immunity that carries forward. Dr. Creech is explicit that monoclonal antibodies do not "teach" the immune system but rather carry it through a dangerous window. He stresses that if an infant happens to contract RSV early in the season before prophylaxis is given, that prior infection should not preclude administering prophylaxis — different RSV subtypes circulate simultaneously, and cross-protection is incomplete.

The panel also discusses prevention beyond prophylaxis: breastfeeding (which confers IgA antibodies from a vaccinated mother), avoiding exposure to cigarette smoke, minimizing crowded daycare environments when feasible, and reinforcing sibling hand hygiene. These measures complement but cannot replace passive immunization. Dr. Munoz raises the evolving understanding that preventing severe RSV in infancy may reduce long-term sequelae, including recurrent wheezing and asthma risk.

In the next episode, "RSV Immunization Rates and Vaccine Hesitancy: Practical Strategies for Clinicians," Dr. Tan and Dr. Simões address the growing challenge of vaccine hesitancy and misinformation, and share evidence-based communication approaches for protecting infants.